Alcohol and Alcoholism Vol. 37, No. 5, pp. 478-484, 2002
© 2002 Medical Council on Alcohol
PROCEEDINGS OF A SYMPOSIUM ENTITLED: 'GABAB RECEPTORS: A TARGET OF NEW TREATMENTS FOR ALCOHOLISM AND DRUG ABUSE'
A POTENTIAL ROLE FOR GABAB AGONISTS IN THE TREATMENT OF PSYCHOSTIMULANT ADDICTION
Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada,
1 Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA and
2 Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
Received 7 March 2002; accepted 27 March 2002
ABSTRACT
— Aims: Here we briefly review the preclinical and clinical evidence that 
-aminobutyric acid (GABAB) agonists may be useful in the treatment of cocaine addiction. An extensive series of studies in rats has demonstrated that baclofen and other GABAB agonists reduce cocaine self-administration in an apparently specific manner. Methods: A number of schedules of reinforcement, including fixed-ratio, progressive-ratio and discrete trials procedures, have been used to model various aspects of cocaine reinforcement and addiction. Results: The results show that systemic pretreatment with baclofen can reduce cocaine intake at doses that do not affect responding for other positive reinforcers, such as food. Direct intracerebral injections of baclofen into the ventral tegmental area also produce a specific reduction in cocaine self-administration, suggesting that an inhibition of dopaminergic neurons may be responsible for the effect. Recent clinical evidence and case reports indicate some therapeutic value for baclofen in controlling cocaine intake and craving, although the evidence from controlled clinical trials has been less than convincing. Perhaps the most intriguing data come from human imaging studies, wherein cocaine addicts report increased cocaine craving and activation of orbital–frontal cortex, anterior cingulate and amygdala when shown videotapes of drug paraphernalia and other addicts taking cocaine. The craving is reduced and the limbic activation is eliminated in cocaine-dependent patients who had been taking baclofen (10–20 mg twice daily) for 7–10 days. Conclusions: Systematic clinical studies of GABAB agonists are needed to determine the extent to which these drugs might serve as tools to promote abstinence in cocaine users seeking treatment for their addiction. Several areas must still be addressed, including potential side-effects that may limit compliance and whether GABAB agonists interfere with other, non-drug-related behaviours.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Markou Neurobiology of nicotine dependence Phil Trans R Soc B, October 12, 2008; 363(1507): 3159 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mombereau, L. Lhuillier, K. Kaupmann, and J. F. Cryan GABAB Receptor-Positive Modulation-Induced Blockade of the Rewarding Properties of Nicotine Is Associated with a Reduction in Nucleus Accumbens {Delta}FosB Accumulation J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 172 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Vocci, J. Acri, and A. Elkashef Medication Development for Addictive Disorders: The State of the Science Am J Psychiatry, August 1, 2005; 162(8): 1432 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Cryan, P. H. Kelly, F. Chaperon, C. Gentsch, C. Mombereau, K. Lingenhoehl, W. Froestl, B. Bettler, K. Kaupmann, and W. P. J. M. Spooren Behavioral Characterization of the Novel GABAB Receptor-Positive Modulator GS39783 (N,N'-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): Anxiolytic-Like Activity without Side Effects Associated with Baclofen or Benzodiazepines J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 952 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Leite-Morris, E. Y. Fukudome, M. H. Shoeb, and G. B. Kaplan GABAB Receptor Activation in the Ventral Tegmental Area Inhibits the Acquisition and Expression of Opiate-Induced Motor Sensitization J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 667 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Colombo, S. Serra, G. Brunetti, G. Atzori, M. Pani, G. Vacca, G. Addolorato, W. Froestl, M. A. M. Carai, and G. L. Gessa THE GABAB RECEPTOR AGONISTS BACLOFEN AND CGP 44532 PREVENT ACQUISITION OF ALCOHOL DRINKING BEHAVIOUR IN ALCOHOL-PREFERRING RATS Alcohol Alcohol., September 1, 2002; 37(5): 499 - 503. [Abstract] [Full Text] [PDF]
|
|